Using modified T cells to target cancer cells in pancreatic tumors
Project 2: Combined CAR-T cell therapy
['FUNDING_OTHER'] · UNIV OF NORTH CAROLINA CHAPEL HILL · NIH-10911131
This study is testing a new treatment for pancreatic cancer that uses specially modified immune cells to find and attack cancer cells, and it's designed to be safe for patients while aiming to improve their treatment outcomes.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIV OF NORTH CAROLINA CHAPEL HILL (nih funded) |
| Locations | 1 site (CHAPEL HILL, UNITED STATES) |
| Trial ID | NIH-10911131 on ClinicalTrials.gov |
What this research studies
This research focuses on developing a new type of cancer treatment using CAR-T cell therapy specifically designed to target pancreatic ductal adenocarcinoma (PDAC). The approach involves modifying T cells to recognize and attack cancer cells that express the B7-H3 protein, which is found in a high percentage of PDAC cases. The study aims to assess the safety and effectiveness of these modified T cells in patients with PDAC, including a built-in safety mechanism to control potential side effects. By addressing the challenges of targeting solid tumors, this research hopes to improve treatment outcomes for patients with pancreatic cancer.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with pancreatic ductal adenocarcinoma who have limited treatment options.
Not a fit: Patients with other types of cancer or those who do not have pancreatic ductal adenocarcinoma may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a novel and effective treatment option for patients with pancreatic cancer, potentially improving survival rates.
How similar studies have performed: Other research has shown promising results with CAR-T cell therapies in hematological malignancies, but this approach for solid tumors like PDAC is still being explored.
Where this research is happening
CHAPEL HILL, UNITED STATES
- UNIV OF NORTH CAROLINA CHAPEL HILL — CHAPEL HILL, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: DOTTI, GIANPIETRO — UNIV OF NORTH CAROLINA CHAPEL HILL
- Study coordinator: DOTTI, GIANPIETRO
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.